What were the primary drivers of revenue growth in the third quarter of 2007?

Revenue growth was primarily driven by increased sales of the TASER X26 product line to the law enforcement market and a significant increase in single cartridge sales, reflecting growth in the installed base. The introduction of the new TASER C2 Personal Protector also contributed to the sales increase.

Why did gross margins decrease despite the increase in net sales?

Gross margins decreased due to several factors including production inefficiencies and rework associated with the new TASER C2 product line, increased warranty reserves on higher sales volume, and rising raw material and transportation costs. These factors led to an increase in the cost of goods sold as a percentage of net sales.

How did the company's legal situation evolve during this period?

The company reported the final settlement of its securities class action litigation for $20 million (partially covered by insurance) and its shareholder derivative litigation for $1.75 million (paid in stock). The company also noted ongoing product liability litigation, with 39 lawsuits pending, which are being defended vigorously and are generally covered by insurance.

What is the company's current liquidity position?

As of September 30, 2007, TASER International had $27.0 million in cash and cash equivalents. The company also had a $10 million line of credit available, with no borrowings outstanding. Management believed these resources, combined with expected operational cash flow, were adequate for at least the next 12 months.

AXON 10-Q Quarterly Report Q3 FY2007 — Revenue, Net Income, EPS

Summary

TASER INTERNATIONAL, INC. (now Axon Enterprise, Inc.) filed its Form 10-Q for the quarterly period ended September 30, 2007, on November 8, 2007. The company demonstrated significant top-line growth, with net sales increasing by 55.8% to $28.5 million in the third quarter of 2007 compared to the same period in 2006. This growth was driven by increased sales of its flagship TASER X26 product line and strong demand for single cartridges, reflecting a growing installed base of devices. The introduction of the new TASER C2 Personal Protector also contributed to the revenue increase. Despite revenue growth, gross margins declined from 63.5% to 56.1% year-over-year, primarily due to inefficiencies and rework costs associated with the new TASER C2 production line, as well as increased warranty reserves and raw material costs. Nevertheless, the company achieved profitability, with net income rising substantially to $6.2 million from $2.4 million in the prior year's quarter. This improvement was partly due to a significant reduction in income tax expense, largely influenced by a research and development tax credit. The company also reported a strong balance sheet with $27.0 million in cash and cash equivalents.

Key Highlights

1Net sales surged by 55.8% to $28.5 million in Q3 2007, compared to Q3 2006, driven by strong demand for TASER X26 and cartridges.
2Introduction of the TASER C2 Personal Protector contributed $1.7 million in sales during its first partial quarter.
3Gross margin decreased to 56.1% from 63.5% due to production inefficiencies with the new C2 model and increased warranty costs.
4Net income more than doubled to $6.2 million ($0.09-$0.10 EPS) in Q3 2007, compared to $2.4 million ($0.04 EPS) in Q3 2006.
5Significant reduction in income tax expense due to a $1.8 million R&D tax credit significantly boosted net income.
6Cash and cash equivalents increased to $27.0 million as of September 30, 2007, from $18.8 million at December 31, 2006.
7The company resolved significant legal proceedings, including a $20 million settlement for securities class action litigation and a $1.75 million settlement for derivative lawsuits.

AXON ENTERPRISE, INC. Quarterly Report for Q3 Ended Sep 30, 2007

Summary

Key Highlights

Frequently Asked Questions